Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Return on Capital Employed (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Return on Capital Employed for 4 consecutive years, with 0.13% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed rose 71.0% to 0.13% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.13% through Dec 2025, up 71.0% year-over-year, with the annual reading at 0.15% for FY2025, 65.0% up from the prior year.
  • Return on Capital Employed hit 0.13% in Q4 2025 for Axsome Therapeutics, up from 0.72% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.13% in Q4 2025 to a low of 0.85% in Q3 2024.
  • Historically, Return on Capital Employed has averaged 0.65% across 4 years, with a median of 0.72% in 2025.
  • Biggest five-year swings in Return on Capital Employed: plummeted -46bps in 2024 and later skyrocketed 71bps in 2025.
  • Year by year, Return on Capital Employed stood at 0.75% in 2022, then surged by 32bps to 0.51% in 2023, then plummeted by -65bps to 0.84% in 2024, then surged by 85bps to 0.13% in 2025.
  • Business Quant data shows Return on Capital Employed for AXSM at 0.13% in Q4 2025, 0.72% in Q3 2025, and 0.83% in Q2 2025.